Drug intelligence / Profile preview

DPI-387

Development stage: Preclinical
Lead developer: Defender Pharmaceuticals
Modality: Small Molecules
Administration: Intranasal

Overview

DPI-387 is a preclinical-stage small molecule drug candidate being developed by Defender Pharmaceuticals for the treatment of Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), and Bipolar Depression. The drug is a scopolamine-related muscarinic acetylcholine receptor antagonist (anticholinergic) designed for intranasal administration. It leverages Defender's intranasal delivery technology and platform molecule, scopolamine, to facilitate rapid delivery to the central nervous system. This approach aims to provide the rapid-acting antidepressant effects associated with scopolamine while optimizing the pharmacokinetic profile through a non-invasive nasal route.

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on DPI-387.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPI-387.

Explore the full profile